Counterpain-PXM

Piroxicam, methyl salicylate, L-menthol, eugenol.

Each gram contains piroxicam 5 mg, methyl salicylate 102 mg, L-menthol 54.3 mg and eugenol 13.7 mg in clear gel base.
Piroxicam is a member of a chemical class of nonsteroidal anti-inflammatory agents, N-heterocyclic carboxamides of 1,2-benzothiazine-1,1-dioxide.

Counterpain-PXM has nonsteroidal anti-inflammatory and analgesic properties.
Counterpain-PXM inhibits the prostaglandin biosynthesis by reversible inhibition of cyclooxygenase enzyme.

Variety of conditions characterized by pain and inflammation eg, osteoarthritis (arthrosis, degenerative joint disease); posttraumatic or acute musculoskeletal disorders including tendinitis, tenosynovitis, periarthritis, sprains, strains and low back pain.

Apply 1 g (corresponding to piroxicam 5 mg) to the affected site 3 or 4 times daily.
Counterpain-PXM is intended for external use only. Do not use with occlusive dressing. Spread the gel evenly on the skin surface.

Patients who have previously shown hypersensitivity to the gel or piroxicam in any of its dosage forms. The potential exists for cross-sensitivity to acetylsalicylic acid and/or other nonsteroidal anti-inflammatory drugs, which may induce the symptoms of asthma, rhinitis, angioedema or urticaria.

To prevent additive toxicity, do not use concomitantly with another dosage form of piroxicam.

If local irritation develops, the use of the gel should be discontinued and appropriate therapy instituted as necessary. Avoid occlusive dressing. Do not apply to the eyes, mucosa or to open skin lesions or skin conditions affecting the site of application.
Use in pregnancy & lactation: The safety of Counterpain-PXM use during pregnancy or lactation has not yet been established. Counterpain-PXM inhibits prostaglandin synthesis and release through a reversible inhibition of the cyclooxygenase enzyme. This effect, as with other nonsteroidal anti-inflammatory agents, has been associated with an increased incidence of dystocia and delayed parturition in pregnant animals when piroxicam administration was continued into late pregnancy. Nonsteroidal anti-inflammatory drugs are also known to induce closure of the ductus arteriosus in infants. A preliminary study indicates that following oral administration, piroxicam exists in maternal milk in a concentration of approximately 1% of that reached in plasma after oral administration. Counterpain-PXM is not recommended for use in nursing mothers as the clinical safety has not been established.

The safety of Counterpain-PXM use during pregnancy or lactation has not yet been established. Counterpain-PXM inhibits prostaglandin synthesis and release through a reversible inhibition of the cyclooxygenase enzyme. This effect, as with other nonsteroidal anti-inflammatory agents, has been associated with an increased incidence of dystocia and delayed parturition in pregnant animals when piroxicam administration was continued into late pregnancy. Nonsteroidal anti-inflammatory drugs are also known to induce closure of the ductus arteriosus in infants. A preliminary study indicates that following oral administration, piroxicam exists in maternal milk in a concentration of approximately 1% of that reached in plasma after oral administration. Counterpain-PXM is not recommended for use in nursing mothers as the clinical safety has not been established.

Adverse effects possibly related to treatment have been infrequently reported. Vast majority of adverse effects involved mild or moderate local irritation, erythema, rash, pityroid desquamation, pruritus and related local reactions at the application site. Mild but transient skin discoloration and staining of clothing have been noted when the gel is not rubbed-in completely.

Store at room temperature (25°-30°C).
Shelf-Life: 2 years.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M02AA07 - piroxicam ; Belongs to the class of non-steroidal antiinflammatory preparations for topical use. Used in the treatment of joint and muscular pains.

T